Alkermes Investigational Site

Canton, Ohio 44720

1 studies enrolling now · 13 studies all time

What they study most

Bipolar I Disorder, Idiopathic Hypersomnia, Major Depressive Disorder, Multiple Sclerosis, Narcolepsy Type 1, Narcolepsy Type 2, Refractory Major Depressive Disorder, Relapsing Remitting Multiple Sclerosis, Schizophrenia, Schizophreniform Disorder

Studies at this site

• A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia — Recruiting now
• Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 — Completed
• A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 — Completed
• A Study of ALKS 3831 in Adults With Schizophrenia — Completed
• A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia — Completed
• A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) — Stopped early
• A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) — Completed
• A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 — Completed
• A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) — Completed
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study — Completed
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study — Completed
• A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) — Completed
• A Long-Term Safety Study of ALKS 5461 — Completed